Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (> 5 mm)

Histopathology

Volumn 33, Issue 5, 1998, Pages 406-413

  Spatz, A ^a   Shaw, H M ^b,c   Crotty, K A ^b,c   Thompson, J F ^b,c   McCarthy, S W ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cell type; Classification; Malignant melanoma; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MITOSIS; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0031739852     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1998.00523.x     Document Type: Article

References (44)

1. Shaw HM, Rivers JK, McCarthy SW, McCarthy WH. Cutaneous melanomas exhibiting unusual biologic behavior. World J. Surg. 1992; 16; 196-202.
2. Mansson-Brahme E, Carstensen J, Erhardt K, Lagerlof B, Ringborg U, Rutqvist LE. Prognostic factors in thin cutaneous malignant melanoma. Cancer 1994; 73; 2324-2332.
3. Rivers JK, McCarthy SW, Shaw HM et al. Patients with thick melanomas surviving at least 10 years: histological, cytometric and HLA analyses. Histopathology 1991; 18; 339-346.
4. Schultz S, Mastrangelo MJ. The pathophysiology and staging of cutaneous malignant melanoma. Semin. Oncol. 1989; 16 (Suppl.): 27-33.
5. McGovern VJ, Mihm MC, Bailly C et al. The classification of malignant melanoma and its histologic reporting. Cancer 1973; 32; 1446-1457.
6. Clark WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969; 29; 705-727.
7. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann. Surg. 1970; 172; 902-908.
8. Barnhill RL. Pathology of Melanocytic Nevi and Malignant Melanoma. Boston: Butterworth-Heinemann Publishers, 1995.
9. McGovern VJ, Shaw HM, Milton GW, Farago GA. Cell type and pigment content as prognostic indicators in cutaneous malignant melanoma. In Ackerman A ed. Pathology of Malignant Melanoma. New York: Masson, 1981; 327-332.
10. Heenan PJ, English DR, Holman DC, Armstrong BK. Survival among patients with clinical stage I cutaneous malignant melanoma diagnosed in Western Australia in 1975/1976 and 1980/1981. Cancer 1991; 68; 2079-2087.
11. Clark WH, Elder DE, Guerry D et al. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 1989; 81; 1893-1904.
12. Harrist TJ, Rigel DS, Day CL et al. 'Microscopic satellites' are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 1984; 53; 2183-2187.
13. Elder DE, Guerry D, Van Horn M et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 1985; 56; 413-418.
14. Sahin S, Rao B, Kopf AW et al. Predicting ten-year survival of patients with primary cutaneous melanoma. Corroboration of a prognostic model. Cancer 1997; 80; 1426-1431.
15. Rogers GS, Kopf AW, Rigel DS et al. Effect of anatomical location on prognosis in patients with clinical stage I melanoma. Arch. Dermatol. 1983; 119; 644-649.
16. Day CL, Sober AJ, Kopf AW et al. A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann. Surg 1981; 193; 436-440.
17. Garbe C, Buttner P, Bertz J et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995; 75; 2492-2498.
18. Schuchter L, Schultz DJ, Synnestvedl M et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. Ann. Intern. Med 1996; 125; 369-375.
19. Cohen HJ, Cox E, Manton K, Woodbury M. Malignant melanoma in the elderly. J. Clin. Oncol. 1987; 5; 100-106.
20. Austin PF, Cruse CW, Lyman G, Schroer K, Glass F, Reintgen DS. Age as a prognostic factor in the malignant melanoma population. Ann. Surg. Oncol. 1994; 1; 487-494.
21. Balch C. Cutaneous melanoma: prognosis and treatment results worldwide. Semin. Surg. Oncol. 1992; 8; 400-414.
22. O'Doherty CJ, Prescott RJ, White H, McIntyre M, Hunter JA. Sex differences in presentation of cutaneous malignant melanoma and in survival from stage I disease. Cancer 1986; 58; 788-792.
23. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996; 78; 427-432.
24. Schmoeckel C, Bockelbrink A, Bockelbrink H, Koutsis J, Braun-Falco O. Low and high risk malignant melanoma: I. Evaluation of clinical and histological prognosticators in 585 cases. Eur. J. Cancer Clin. Oncol. 1983; 19; 227-235.
25. Sondergaard K, Schou G. Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases. Virchows Arch. A Pathol. Anat. Histopathol. 1985; 406; 179-195.
26. Van der Esch EP, Cascinelli N, Preda F, Morabito A, Bufalino R. Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer 1981; 48; 1668-1673.
27. Huvos AG, Shah AP, Mike V. Prognostic factors in cutaneous malignant melanoma. A comparative study of long term and short term survivors. Hum. Pathol. 1974; 5; 347-357.
28. Hacene K, Le Doussal V, Brunet M, Lemoine F, Guerin P, Herbert H. Prognostic index for clinical stage I cutaneous malignant melanoma. Cancer Res. 1983; 43; 2991-2996.
29. Shaw HM, Balch CM, Soong SJ, Milton GW, McCarthy WH. Prognostic histopathological features in malignant melanoma. Pathology 1985; 17; 271-274.
30. Sylaidis P, Gordon D, Rigby H, Kenealy J. Follow-up requirements for thick cutaneous melanoma. Br. J. Plast. Surg. 1997; 50; 349-353.
31. Day CL, Lew RA, Mihm MC et al. A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 5.65 mm in thickness. The importance of revealing alternative Cox models. Ann. Surg. 1982; 195; 44-49.
32. Coit D, Sauven P, Brennan M. Prognosis of thick cutaneous melanoma of the trunk and extremity. Arch. Surg. 1990; 125; 322-326.
33. Blessing K, McLaren KM, McLean A, Davidson P. Thick malignant melanomas (> 3 mm Breslow) with good clinical outcome: a histological study and survival analysis. Histopathology 1991; 18; 143-148.
34. Schneebaum S, Briele HA, Walker MJ et al. Cutaneous thick melanoma. Prognosis and treatment. Arch. Surg. 1987; 122; 707-711.
35. McCarthy WH, Shaw HM, McCarthy SW, Rivers JK, Thompson JF. Cutaneous melanomas that defy conventional prognostic indicators. Semin. Oncol. 1996; 23; 709-713.
36. Vollmer RT. Malignant melanoma. A multivariate analysis of prognostic factors. Pathol. Ann. 1989; 24; 383-407.
37. Prade M, Bognel C, Charpentier P et al. Malignant melanoma of the skin: prognostic factors derived from a multifactorial analysis of 239 cases. Am. J. Dermatopathol. 1982; 4; 411-412.
38. Smithers BM, McLeod GR, Little JH. Desmoplastic, neural transforming and neurotropic melanoma: a review of 45 cases. Aust. N.Z. J. Surg. 1990; 60; 966-972.
39. Bruijn JA, Mihm MC, Barnhill RL. Desmoplastic melanoma. Histopathology 1992; 20; 197-205.
40. Baer SC, Schultz D, Synnestvedt M, Elder DE. Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma. Cancer 1995; 76; 2242-2247.
41. Fallowfield ME, Cook MG. Vascular invasion in malignant melanomas. An independent prognostic variable? Am. J. Surg. Pathol 1989; 13; 217-220.
42. Chi H-I, Uyeda Y, Umebayashi Y, Otsuka F. Epithelioid cell melanomas have greater DNA ploidy abnormalities than spindle cell melanomas: cytological evidence for a higher malignant potential of the former. Arch. Dermatol. Res. 1993; 285; 410-414.
43. Umebayashi Y, Otsuka F. Prognostic significance in melanoma of nuclear DNA content measured by a microfluorimetric method. Arch. Dermatol. Res. 1995; 287; 718-722.
44. Cochran AJ, Heenan P. The classification of melanoma: time for a further revision? Melanoma Res. 1997; 7; 4-9.